{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:36:39Z","timestamp":1791606999005,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008381","name":"Cancer University Institute Toulouse Oncopole","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.euo.2023.09.020","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:41:49Z","timestamp":1696621309000},"page":"494-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Surgery with or Without Darolutamide in High-risk and\/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3831-1632","authenticated-orcid":false,"given":"Giorgio","family":"Calleris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Cabarrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.09.020_b0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/pros.24184","article-title":"Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores","volume":"81","author":"Wenzel","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2023.09.020_b0010","unstructured":"Mottet N, Cornford P, van den Bergh R, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. Presented at the EAU Annual Congress Milan 2023."},{"key":"10.1016\/j.euo.2023.09.020_b0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.urolonc.2019.12.014","article-title":"Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy","volume":"38","author":"Knipper","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2340\/sju.v58.7318","article-title":"Salvage radiotherapy after radical prostatectomy: functional outcomes in the LAPPRO trial after 8-year follow-up","volume":"58","author":"Carlsson","year":"2023","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2023.09.020_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006019","article-title":"Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"2006","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2023.09.020_b0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2023.09.020_b0040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0045","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2022.03.031","article-title":"Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Rajwa","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.906370","article-title":"Neoadjuvant chemohormonal therapy in prostate cancer before radical prostatectomy: a systematic review and meta-analysis","volume":"12","author":"Ge","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0060","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","article-title":"Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials","volume":"205","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0065","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0070","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0075","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.09.020_b0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41391-022-00496-8","article-title":"NEAR trial: a single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2023.09.020_b0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0090","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0095","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/jpm13040641","article-title":"Neoadjuvant androgen receptor signaling inhibitors before radical prostatectomy for non-metastatic advanced prostate cancer: a systematic review","volume":"13","author":"Yanagisawa","year":"2023","journal-title":"J Pers Med"},{"issue":"6_suppl","key":"10.1016\/j.euo.2023.09.020_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS383","volume":"38","author":"Taplin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0105","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.09.020_b0110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.09.020_b0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.09.020_b0120","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41391-022-00533-6","article-title":"LHRH sparing therapy in patients with chemotherapy-na\u00efve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial","volume":"25","author":"Ohlmann","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2023.09.020_b0125","article-title":"A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532)","volume":"41(6_suppl):160","author":"Tombal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0130","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0140","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JU.0000000000002803","article-title":"Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis","volume":"208","author":"Ravi","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0145","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","article-title":"Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0150","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0155","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.euo.2023.09.020_b0160","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00345-021-03611-x","article-title":"Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review","volume":"39","author":"Devos","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2021.07.027","article-title":"Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: development and external validation of novel risk groups","volume":"81","author":"Mazzone","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0170","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.21.02741","article-title":"Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer: analysis of NRG oncology\/RTOG 9601","volume":"40","author":"Jackson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0175","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.eururo.2007.01.015","article-title":"Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy","volume":"51","author":"Simmons","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0180","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.euo.2018.07.008","article-title":"First postprostatectomy ultrasensitive prostate-specific antigen predicts survival in patients with high-risk prostate cancer pathology","volume":"1","author":"Kang","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0185","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.09.020_b0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","article-title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Wenzel","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2023.09.020_b0195","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1200\/JCO.2023.41.16_suppl.5097","article-title":"Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR","volume":"41","author":"Morgans","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.09.020_b0200","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/iju.14994","article-title":"Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial","volume":"29","author":"Yang","year":"2022","journal-title":"Int J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:24:28Z","timestamp":1715822668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2588931123002122"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.09.020","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgery with or Without Darolutamide in High-risk and\/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}